WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010024271) MODIFIED ANTI-HEPARIN/PF4 COMPLEX ANTIBODY AND HIT ANTIBODY STANDARD
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/024271    International Application No.:    PCT/JP2009/064828
Publication Date: 04.03.2010 International Filing Date: 26.08.2009
IPC:
C07K 16/18 (2006.01), C12P 21/08 (2006.01), G01N 33/53 (2006.01)
Applicants: Mitsubishi Chemical Medience Corporation [JP/JP]; 2-8, Shibaura 4-chome, Minato-ku, Tokyo 1088559 (JP) (For All Designated States Except US).
HOSHINO Nobuhiro [JP/JP]; (JP) (For US Only)
Inventors: HOSHINO Nobuhiro; (JP)
Agent: MORITA Kenichi; (JP)
Priority Data:
2008-218801 27.08.2008 JP
Title (EN) MODIFIED ANTI-HEPARIN/PF4 COMPLEX ANTIBODY AND HIT ANTIBODY STANDARD
(FR) ANTICORPS ANTI-COMPLEXE HÉPARINE/PF4 MODIFIÉ ET ANTICORPS ANTI-HIT STANDARD
(JA) 修飾抗ヘパリン/PF4複合体抗体及びHIT抗体標準品
Abstract: front page image
(EN)Disclosed is a modified antibody which enables the quantitative measurement of the quantity of a heparin/PF4 complex, which is a causal factor of heparin-induced thrombocytopenia (HIT), without the influence of the presence of PF4 and which can be used as an HIT antibody standard specific to a heparin/PF4 complex. The modified antibody comprises a monoclonal antibody produced by immunizing an animal (excluding a human body) with a heparin/PF4 complex and a human IgG or a human IgG-derived antibody fragment conjugated to the monoclonal antibody.
(FR)La présente invention concerne un anticorps modifié, qui permet la mesure quantitative de la quantité d’un complexe héparine/PF4, qui est un facteur causal de la thrombocytopénie induite par l’héparine (HIT), sans l’influence de la présence de PF4 et qui peut être utilisé en tant qu’anticorps anti-HIT spécifique d’un complexe héparine/PF4. L’anticorps modifié comprend un anticorps monoclonal produit par immunisation d’un animal (à l’exclusion d’un corps humain) avec un complexe héparine/PF4 et un fragment d’anticorps d’IgG humain ou un fragment d’anticorps dérivé d’IgG humain conjugué à l’anticorps monoclonal.
(JA) ヘパリン起因性血小板減少症(HIT)の発症因子であるヘパリン/PF4複合体の量を、PF4単体の存在に影響を受けることなく、定量的に測定可能であって、しかも、ヘパリン/PF4複合体特異的なHIT抗体標準品としても使用可能な、修飾抗体を提供する。  前記修飾抗体は、ヘパリン/PF4複合体を動物(ヒトを除く)に免疫して得られるモノクローナル抗体に、ヒトIgGあるいはヒトIgG由来抗体フラグメントを結合させたものである。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)